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-        performing a preparatory dosimetric study to use a 
dose-escalation 
-        runnning a multicentric phase III randomized dose-
painting prospective clinical trial, Spectro Glio, with 
centralized contouring and online quality control of the 
dosimetry for the experimental arm 
-      preparing methods for analysis of multimodal imaging 
gathered during this trial in order to further improve the 
definition of the optimal Biological Target Volume. 
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Introduction: In literature the term « dose reconstruction” 
has been used for several concepts. In radioprotection it is 
defined as the accumulation of radiation doses received by 
workers or patients (radiology e.g.). In this presentation the 
focus is on radiotherapy applications and more concretely on 
the measure of the actually delivered dose, received by the 
patient during a dynamic treatment. As treatments are 
becoming more and more complex, using flattening filter free 
beams, high dose rates, dose escalation, hypofractionation, 
and gating or tracking strategies, while irradiating moving 
geometries, one can expect that the actually delivered dose 
will deviate from the planned one. Delivery QAs in a 
homogeneous phantom using in plane gamma analysis do not 
seem adequate. 
Overview delivery QA methods: Setup-
uncertainties/robustness: Can be evaluated by convolving the 
PDF of the tumor position with the dose. Convolving this PDF 
with the 2-D fluence of each individual beam corrects for the 
shift invariance assumption. An alternative method is 
modifying the isocenter position of each individual beam in 
the RTPlan file for dose reconstruction. 
Static delivery QA of a single fraction: In EPID dosimetry the 
exit fluence measured by the portal imaging device is 
reconstructed to dose in the patient. On a Tomotherapy 
machine, the MVCT data obtained during the treatment can 
be used for this purpose. The method of Feygelman et al uses 
a phantom measurement-based perturbation map to include 
the impact of dynamic delivery in the TPS dose. This method 
can also be used to estimate the impact of patient motion. 
Machine log files can be used and dose calculation can be 
performed on cone beam CT or MVCT. 
4D Intra-fraction dose accumulation: The dose corresponding 
to the original RTPlan is calculated on the different CT 
phases of the 4D CT. Deformable registration between the 
phases allows warping the dose to the reference scan for 
dose accumulation. This does not consider the interplay 
effect. A more precise approach is to use the machine log 
files allowing synchronization of the individual CPs with the 
breathing phase. Phase specific RTPlan files are generated to 
calculate the phase specific dose. An alternative is the 
uniform time sampling technique introduced by Litzenberg et 
al. using a dedicated MC dose calculation engine. Even more 
precise would be to calculate dose on a 4D cone beam CT.  
Inter-fraction dose accumulation: For each individual fraction 
the log files are used to calculate the delivered dose on the 
cone beam CT or MVCT images. All fraction scans are 
deformed to the planning CT for dose warping. The use of 
congruent energy/mass warping is preferable for this 
application as the geometry change can be more important. 
There remain unanswered questions though: what is the 
impact of voxels being lost (weight loss, tumor shrinkage, 
OAR shrinkage, …). The quantity “dose” might not be optimal 
for accumulation in shrinking organs.  
Conclusion: The dose reconstruction methods are rapidly 
evolving. Different levels of approximation and accuracy are 
possible. A further evolution in in-room imaging such as 4D 
cone beam CT might increase precision and provide the 
actually delivered dose. This will even be more relevant in 
proton therapy. The knowledge of the delivered dose might 
lead to a better understanding of biological effects related to 
the treatment and to more robust planning strategies. The 
accumulation of inter-fraction dose remains a challenge 
where the physical concept of dose probably needs to be 
replaced by organ specific parameters that can be 
accumulated, such as the absolute volume of a parallel organ 
(e.g. the parotids) that receives a dose below a certain 
threshold. 
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Introduction:Stereotactic body radiation therapy is a rapidly 
expanding technique, requiring high delivery accuracy 
because of the applied hypofractionation with high fraction 
and total doses. At conventional linacs, doses can be 
delivered with coplanar and non-coplanar beam 
arrangements, while dedicated machines like the Cyberknife 
and the Vero have their own unique treatment approaches. 
Performing unbiased plan comparisons may be time 
consuming and difficult due to user dependency and the trial-
and-error procedure needed in manual planning. In our 
institute, a home-made optimizer, Erasmus-iCycle (Breedveld 
et al., Med Phys. 2012; 39(2): 951), has been developed for 
fully automated plan generation. Due to the automation, this 
optimizer is suited for unbiased plan comparisons between 
various treatment approaches, based on large numbers of 
generated plans. Using Erasmus-iCycle, in Rotterdam, 
automated VMAT plan generation is now in full clinical use 
for prostate, head and neck, and cervical cancer. 
Material & Method:Erasmus-iCycle can be used for IMRT 
fluence optimization and individualized beam angle selection 
(iBAS). Given an input beam set containing all feasible beam 
directions, iBAS starts with an empty plan, i.e. zero beams 
(N=0), and at each step, it creates an N+1 beam plan, 
selecting the most optimal direction to be added to the N-
beam plan. Automated Erasmus-iCycle plan creation is 
steered by a list of planning requirements, a so-called 
wishlist, containing clinical constraints and objectives. The 
same wishlist is used for all patients of a certain treatment 
protocol (e.g. SBRT prostate cancer). Objectives are 
prioritized to give high priority to fulfilment of the most 
important clinical goals, compared to less important aims. 
Generally, PTV coverage has the highest priority. In 
comparisons of treatment strategies, the aim is to have equal 
PTV coverage for all strategies, allowing comparison of 
involved strategies based on doses delivered to the OAR. 
Results:An overview of the Erasmus-iCycle optimizer will be 
provided, with focus on automated beam angle selection. 
Results on plan comparisons for different beam geometries 
will be presented for prostate SBRT. In particular, non-
coplanar Cyberknife treatment with an MLC or circular cones, 
will be compared to treatments at a linac, including VMAT. 
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Replacement of iBAS by beam angle class solutions will be 
discussed as well. 
Conclusion:Automated plan generation, including iBAS, is a 
pre-requisite for systematic, unbiased comparison of the 
impact of beam arrangements in SBRT.  
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Stereotactic Body Radiotherapy (SBRT) involves delivery of a 
high dose with stereotactic precision in only a few fractions. 
Usual treatment sites are lung, liver, spine, prostate and 
often treatment is delivered using a volumetric modulated 
arc therapy (VMAT) technique. With conventional dose rates, 
the highest fraction dose treatments can take 7-12 minutes 
delivery time. This can be reduced to 2-3 minutes by using 
flattening filter free (FFF) beams with dose rates up to 2400 
MU/min. Treatment planning studies have shown similar plan 
quality using FFF or flattened beams. Faster treatments 
implies less time for possible intrafraction motion. However, 
not all measured intrafraction motions could be correlated 
with treatment time. Conversely, due to the fast delivery, 
brief intrafraction shifts may lead to larger dosimetric 
differences than for slower deliveries. In addition, interplay 
effects of a respiratory moving tumor can be larger for the 
faster deliveries. Whether or not all this knowledge can lead 
to margin reduction may also depend on the margins that 
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The treatment of cancer with radiopharmaceuticals is 
expanding rapidly in terms of the numbers and range of 
procedures performed. The majority of treatments are 
currently performed with fixed activity administrations, 
sometimes modified according to patient weight or body 
surface area, as  is common practice for chemotherapy 
procedures. Personalised dosimetry-based treatment 
planning, as is routine for external beam radiotherapy 
(EBRT), is now mandated by a new European directive (EU 
directive 2013/59) and presents a number of unique 
challenges. 
There is increasing evidence for strong correlations between 
the absorbed doses delivered to tumours and to organs-at-
risk and response and toxicity (Strigari et al Eur J Nucl Med 
Mol Imaging 2014).  While it is not possible to determine an 
absorbed dose that will be delivered to a tumour or organ 
prior to administration, due to inter-patient variations in 
biokinetics, it is usually found that intra-patient variations 
are much reduced, so that uptake and retention may be 
accurately predicted from a previous therapy study or from a 
tracer study. 
Dosimetry for treatment planning of Molecular Radiotherapy 
(MRT) can be performed with quantitative imaging (SPECT, 
planar or PET) or from external probe measurements. Whole-
body retention measurements allow the calculation of whole-
body dosimetry which, as a surrogate for bone marrow 
dosimetry, has been used for several therapy procedures 
including I-131 mIBG treatment of neuroblastoma in 
paediatrics, uptake measurements for the treatment of 
benign thyroid disease with radioiodine and 
radioimmunotherapy for NHL. Dosimetry based on organ 
dosimetry has been less utilised, although the absorbed doses 
delivered to kidneys are recognised as a limiting factor in 
peptide receptor radionuclide therapy. 
The role of treatment planning is of particular relevance to 
an emerging cohort of commercially driven radiotherapeutics 
and has attracted conflicting approaches. The treatment of 
HCC and liver metastases with intra-arterial injections of 
radiolabelled microspheres has been developed for Y-90 and 
Ho-166 resin and glass microspheres. Initial treatment 
protocols were based on body surface area, although have 
become increasingly sophisticated. Two industry sponsored 
multi-centre international studies are currently in 
preparation to ascertain the correlation of the absorbed 
doses with response on which future treatments would be 
based. Conversely, Ra-223 has recently been at the forefront 
of a new wave of alpha based therapies, although is currently 
administered as a chemotherapeutic with a series of six 
weight-based administrations at 4 week intervals. 
A number of challenges are to be addressed as prospective 
treatment planning is introduced. Tracer administrations I-
131 NaI are considered to cause a ‘stunning’ effect whereby 
further uptake of a therapeutic administration is mitigated, 
although as yet there are no systematic studies to 
demonstrate this effect or its severity. Further, the %ID of 
uptake from a tracer administration will not necessarily 
predict the uptake of a therapeutic administration that may 
be two orders of magnitude higher. This may entail the 
application of correction factors. Further issues to be 
resolved are that patient-specific factors, that may include 
considerations of previous treatments or the time to recovery 
of marrow depression, preclude rigid protocols that will 
necessarily be targeted to the most vulnerable of patients 
and will therefore be sub-optimal for the majority. 
In conclusion, as outstanding challenges are addressed and 
resolved, the ability to directly image the uptake and 
retention of a radiotherapeutic in vivo and the adoption of 
treatment schedules that allow time between sequential 
administrations to calculate the absorbed doses delivered 
and to modify further treatments accordingly, offer the 
potential for highly personalised treatment planning for MRT 
that can only lead to improved efficacy. 
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Bone metastases are a frequent consequence from a wide 
range of malignancies and are associated with a high degree 
of morbidity. More than 90% of patients with metastatic 
castrate resist-ant prostate cancer (mCRPC) have bone 
metastases, often as the only significant metastatic site [1]. 
At diagnosis, approximately10-15% of men presenting with 
prostate cancer have bone metastases at diagnosis. These 
